Aarthi Narayanan, Associate Professor, and Lance Liotta, Associate Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), are conducting three studies to evaluate the therapeutic efficacy of candidate interventions for COVID-19 in mouse modules.
For the first study, the researchers hope to validate the survival benefit provided by a physician.
For this study, the researchers intravenously inject ACE2 animals with SARS-CoV-2 and follow them up to seven days after infection.
As part of the second study, they are working to determine what survival benefit therapeutic provides if another course or dosing strategy is needed. Again, the researchers followed the animals for up to seven days after infection.
For the third experiment, the researchers infiltrate ACE2 animals internally with SARS-CoV-2 and then inoculate the animals on the third day after infection, when which is expected to increase viral loads in the lungs.
The researchers received $ 103,620 from Targeted Pharmaceuticals, LLC, for this project. Funding began in December 2020 and will end at the end of February 2021.